Hexosept-Rn (Suppositories) Instructions for Use
Marketing Authorization Holder
Rubicon, LLC (Republic of Belarus)
ATC Code
G01AX (Other antimicrobial drugs and antiseptics)
Active Substance
Chlorhexidine (Rec.INN registered by WHO)
Dosage Form
| Hexosept-Rn | Vaginal suppositories 16 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
Vaginal suppositories white or yellowish-white in color, torpedo-shaped; a funnel-shaped depression is allowed; an air core may be present on the longitudinal section.
| 1 supp. | |
| Chlorhexidine digluconate | 16 mg, |
| Which corresponds to the content of a 20% chlorhexidine digluconate solution | 85.2 mg |
Excipients : macrogol 1000 (polyethylene oxide 1000) – up to 3100 mg.
5 pcs. – contour cell packs (2) – cardboard boxes.
Clinical-Pharmacological Group
Topical antiseptic for use in gynecology
Pharmacotherapeutic Group
Antiseptic
Pharmacological Action
Antiseptic agent. Chlorhexidine exhibits bactericidal action (against gram-positive and gram-negative bacteria) – at a temperature of 22°C (71.6°F) and exposure for 1 min; fungicidal action at a temperature of 22°C (71.6°F) and exposure for 10 min; virucidal action (against lipophilic viruses).
It acts on bacterial spores only at elevated temperatures. It is stable, and after skin treatment, it remains on it in a certain amount sufficient to manifest a bactericidal effect. It retains activity (although somewhat reduced) in the presence of blood, pus, various secretions, and organic substances.
It does not have a damaging effect on items made of glass, plastic, and metals.
Pharmacokinetics
When applied externally and locally, it is not absorbed into the systemic circulation and does not have a systemic effect.
Indications
Trichomonal colpitis, cervical erosion, vulvar itching, prevention of venereal diseases (including gonorrhea, syphilis, trichomoniasis, chlamydia, ureaplasmosis); prevention of infectious and inflammatory complications in obstetrics and gynecology (before surgical treatment of gynecological diseases, before childbirth, abortion, before and after insertion of an IUD, before and after diathermocoagulation of the cervix, before intrauterine examinations); treatment of bacterial vaginosis, colpitis (including nonspecific, mixed, trichomonal).
ICD codes
| ICD-10 code | Indication |
| A59 | Trichomoniasis |
| L29.2 | Pruritus vulvae |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N76 | Other inflammatory diseases of vagina and vulva |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| N86 | Erosion and ectropion of cervix |
| N89.8 | Other noninflammatory disorders of vagina |
| Z29.8 | Other specified prophylactic measures |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1A92 | Trichomoniasis |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| GA15.1 | Erosion or ectropion of cervix |
| GA42.0 | Pruritus vulvae |
| GC42.1 | Painful intercourse |
| MF3A | Vaginal discharge |
| QB9A | Preparatory procedures for subsequent treatment |
| QC05.Z | Prophylactic measures, unspecified |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
| GA1Z | Unspecified noninflammatory disorders of female genital tract |
| XA1LK7 | Vagina |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For treatment of infectious and inflammatory diseases (trichomonal colpitis, bacterial vaginosis, nonspecific colpitis), administer one 16 mg vaginal suppository twice daily, for 7 to 10 days.
For prevention of infectious complications before gynecological surgery, childbirth, abortion, IUD insertion, or diathermocoagulation, administer one suppository twice daily for 5 to 7 days prior to the procedure.
For post-interventional care, administer one suppository twice daily for 5 to 7 days following the procedure.
For prevention of venereal diseases, administer one suppository as soon as possible, but no later than two hours after sexual intercourse.
Thoroughly wash hands before and after administration. Insert the suppository deeply into the vagina while lying on your back with knees bent.
For optimal efficacy, complete the full prescribed course of treatment, even if symptoms improve earlier.
Discontinue use immediately and consult a physician if bloody vaginal discharge, severe itching, rash, or burning occurs.
Adverse Reactions
Allergic reactions: skin rash, itching, severe allergic reactions, including anaphylaxis.
Skin and subcutaneous tissue disorders: dry skin, itching, dermatitis, photosensitivity.
Local reactions: enamel staining, tartar deposition, taste disturbance.
With vaginal use allergic reactions (rash, itching), burning are possible; very rarely – anaphylactic reactions; in some cases – bloody discharge from the vagina.
Contraindications
Hypersensitivity to chlorhexidine.
Use in Pregnancy and Lactation
If it is necessary to use during pregnancy and breastfeeding, the expected benefit of therapy for the mother and the possible risk to the fetus should be weighed.
Pediatric Use
Use with caution in children.
Geriatric Use
There are currently no restrictions for use in elderly patients.
Special Precautions
With intravaginal use, in case of bloody discharge from the vagina, the use of chlorhexidine should be discontinued.
Avoid getting chlorhexidine into the eyes (except for a special dosage form intended for use in ophthalmology), as well as contact with the meninges and the auditory nerve.
Drug Interactions
It is used in a neutral environment; at pH 5-8 the difference in activity is small; at pH above 8, a precipitate forms.
It is not used in combination with anionic compounds, including soap.
It is incompatible with carbonates, chlorides, phosphates, borates, sulfates, and citrates.
The use of hard water reduces bactericidal properties.
It is compatible with medicinal products containing a cationic group (benzalkonium chloride, cetrimonium bromide).
Storage Conditions
Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Kagocel pills 12mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Noopept, pills 10mg, 50pcs
Picamilon pills 50mg, 60pcs
OKI, sachets 80mg 2g, 12pcs
Cortexin, 10mg, 5ml, 10pcs
Daivobet, ointment, 30g
Actovegin pills 200mg, 50pcs
Belosalic, lotion solution for external use spray 100ml
Ingavirin capsules 90mg, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Nootropil pills 800mg, 30pcs 